Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663429 · ClinicalTrials.gov registry record · Phase 2
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
A Phase 2 study, sponsored by Callisto Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00663429: Completed Phase 2 study, sponsored by Callisto Pharmaceuticals.
NCT00663429 is a Phase 2 study that has completed, run by Callisto Pharmaceuticals. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00663429, a Phase 2 study, has completed, sponsored by Callisto Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is an extension study to the Callisto protocol CP-106. Subjects must have completed all 12 treatment cycles of CP-106 without disease progression as per RECIST criteria,to be eligible to to be enrolled in this study. This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing) despite standard therapy (octreotide) or progression of neuroendocrine tumor(s).
Interventions
- DRUG Atiprimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00663429
The ClinicalTrials.gov registry entry for NCT00663429 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Callisto Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atiprimod is the first listed.
NCT00663429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00663429 about?
NCT00663429 is a clinical study titled "Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma". This study is an extension study to the Callisto protocol CP-106. Subjects must have completed all 12 treatment cycles of CP-106 without disease progression as per RECIST criteria,to be eligible to to be enrolled in this study. This study will evaluate the safety and efficacy of atiprimod treatment ...
What is the current status of trial NCT00663429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-11. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00663429?
The interventions under investigation include: Atiprimod (DRUG).
Who is sponsoring clinical trial NCT00663429?
This trial is sponsored by Callisto Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.